Scarica l'app Stockscreener
0.00
100.00%
-93.80
Precedente Chiudi:
$93.80
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$80.00M
Reddito:
-
Utile/perdita netta:
$-75.52M
Rapporto P/E:
0.00
EPS:
-2.88
Flusso di cassa netto:
$-56.92M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$884.98
Aerovate Therapeutics Inc Stock (AVTE) Company Profile
Nome
Aerovate Therapeutics Inc
Settore
Industria
Telefono
617-443-2400
Indirizzo
930 WINTER STREET, WALTHAM
Confronta AVTE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AVTE
Aerovate Therapeutics Inc
|
0.00 | 80.00M | 0 | -75.52M | -56.92M | -2.88 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Aerovate Therapeutics Inc Stock (AVTE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-07 | Iniziato | Wedbush | Outperform |
| 2025-05-05 | Iniziato | Stifel | Buy |
| 2025-05-02 | Iniziato | TD Cowen | Buy |
| 2024-06-18 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-06-18 | Downgrade | TD Cowen | Buy → Hold |
| 2024-06-18 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-06-17 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-06-17 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-06-17 | Downgrade | Wedbush | Outperform → Neutral |
| 2024-03-25 | Ripresa | Jefferies | Buy |
| 2023-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2022-12-06 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-09-19 | Ripresa | Wedbush | Outperform |
| 2022-08-16 | Downgrade | BTIG Research | Buy → Neutral |
| 2022-02-11 | Iniziato | BTIG Research | Buy |
| 2021-07-26 | Iniziato | Cowen | Outperform |
| 2021-07-26 | Iniziato | Evercore ISI | Outperform |
| 2021-07-26 | Iniziato | Jefferies | Buy |
| 2021-07-26 | Iniziato | Wedbush | Outperform |
Mostra tutto
Aerovate Therapeutics Inc Borsa (AVTE) Ultime notizie
BNP Paribas Financial Markets Makes New Investment in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Jade Biosciences Secures Massive $300M Funding After Nasdaq Debut, First Clinical Trial Set for 2025 - Stock Titan
Aerovate Therapeutics (AVTE) to Release Earnings on Monday - Defense World
Renaissance Technologies LLC Buys 26,700 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Stifel Nicolaus Initiates Coverage on Jade Biosciences With Buy Rating, $19 Price Target - marketscreener.com
Stifel initiates Jade Biosciences stock with a Buy, $19 target - Investing.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of Shareholders - marketscreener.com
Aerovate Therapeutics, Inc. Announces Board Changes - marketscreener.com
Aerovate Therapeutics Declares Special Cash Dividend In Connection With The Proposed Merger With Jade Biosciences - marketscreener.com
TD Cowen Initiates Coverage on Jade Biosciences With Buy Rating - marketscreener.com
TD Cowen starts Jade Biosciences coverage with Buy rating - Investing.com
Aerovate Therapeutics Completes Merger with Jade Biosciences - TipRanks
Aerovate Therapeutics Announces Range of Expected Cash Dividend - marketscreener.com
Aerovate Therapeutics Announces Range Of Expected Cash Dividend - marketscreener.com
RTW Biotech Opportunities’ Jade Biosciences merges with Aerovate Therapeutics - QuotedData
Jade Biosciences Highlights JADE-001 Progress in Presentation - TipRanks
Aerovate Therapeutics Inc (AVTE)’s financial ratios: A comprehensive overview - DWinneX
Aerovate Therapeutics (AVTE) Options Set for Delisting | AVTE St - GuruFocus
Aerovate Therapeutics (AVTE) Options Set for Delisting | AVTE Stock News - GuruFocus
Traders Buy Large Volume of Call Options on Aerovate Therapeutics (NASDAQ:AVTE) - Defense World
Jade Biosciences closes merger with Aerovate Therapeutics - Business in Vancouver
Aerovate Therapeutics Inc (AVTE) gets rating Downgrade from Wells Fargo - knoxdaily.com
Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously ... - Bluefield Daily Telegraph
Jade Biosciences Completes Closing of Merger with Aerovate - GlobeNewswire
Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 Million - Benzinga
Russell Investments Group Ltd. Boosts Stake in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Aerovate Therapeutics, Inc. SEC 10-Q Report - TradingView
Aerovate Therapeutics Inc (AVTE) Performance and Fundamentals Dashboard tells a completely different story - Sete News
AVTE’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH) - Barchart.com
AVTE Shares Experience Decline in Value - knoxdaily.com
Aerovate (AVTE) Approves 1-for-35 Reverse Stock Split Amid Merge - GuruFocus
Aerovate approves reverse split ahead of Jade merger By Investing.com - Investing.com South Africa
Aerovate Therapeutics and Jade Biosciences Merger Approved - citybiz
Aerovate Stockholders Approve Merger Proposal With Jade Biosciences - Nasdaq
Aerovate approves reverse split ahead of Jade merger - Investing.com
Aerovate (AVTE) Stockholders Approve Merger with Jade Biosciences | AVTE Stock News - GuruFocus
Aerovate Therapeutics Approves Merger with Jade Biosciences - TipRanks
Aerovate Therapeutics stockholders approve proposed merger with Jade Biosciences - TipRanks
Aerovate Therapeutics Stockholders Approve Proposed Merger With Jade Biosciences And All Related Proposals - marketscreener.com
Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals - PR Newswire
Halper Sadeh LLP, Aerovate Therapeutics, Inc., Staffing 360 Solutions, Inc., Allovir - The Bradford Era
Aerovate announces $69.6 million special dividend By Investing.com - Investing.com India
Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences - The Malaysian Reserve
Aerovate announces $69.6 million special dividend - Investing.com Australia
Aerovate signals cash dividend ahead of Jade merger By Investing.com - Investing.com South Africa
Aerovate Therapeutics Stock Bucks Broader Market Sell-Off Over Dividend Announcement: Stock Rises But Retail’s Unmoved - NewsBreak: Local News & Alerts
Aerovate Therapeutics Announces Merger with Jade Biosciences - TipRanks
Aerovate signals cash dividend ahead of Jade merger - Investing.com
Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences - PR Newswire
Aerovate Therapeutics Inc Azioni (AVTE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):